Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 1Sarcoma 1Rectal Neoplasms 1Plasmacytoma 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Margins of Excision 1Homologous Recombination Deficient Solid Tumors 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Acrocephalosyndactylia 1

Interventions

Fluorouracil 219Leucovorin 202Oxaliplatin 192Irinotecan 150Bevacizumab 110Capecitabine 94Cetuximab 90Folfox protocol 54Chemotherapy, Adjuvant 36Panitumumab 30Colonoscopy 30pembrolizumab 23Drug Therapy 23Nivolumab 22Magnetic Resonance Spectroscopy 22Gemcitabine 21Blood Specimen Collection 20Radiotherapy 19Floxuridine 19Biopsy 19Neoadjuvant Therapy 18Laparoscopy 18IFL protocol 18Early Intervention, Educational 18Celecoxib 18Surveys and Questionnaires 17Surgical Procedures, Operative 16Immunohistochemistry 16Exercise 16trifluridine tipiracil drug combination 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × Drug Combinations × Clear all
NCT02882269 2016-08-30

Neoadjuvant Chemotherapy for the Treatment of Resectable Locally Advanced Colon Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2/3 Unknown
400 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡